Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing: Experts Answer Clinician Questions

In this episode, George D. Demetri, MD; Alexander Drilon, MD; and Pashtoon Kasi, MD, answer questions about NTRK fusion testing and TRK inhibitor therapy for patients with advanced solid tumors, with topics including:Best practices in testing for NTRK fusions in solid tumorsOptimal use of approved TRK inhibitorsKey adverse events with TRK inhibitors and management strategiesEmerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agentsPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental Therapeutics  Director, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, Thoracic OncologyMemorial Sloan Kettering Cancer CenterNew York, New YorkPashtoon Kasi, MDAssistant ProfessorCollege of Medicine and OncologyHolden Comprehensive Cancer CenterUniversity of IowaIowa City, IowaContent based on an online CME program supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc. and Genentech.Link to full program: https://bit.ly/2PN0BWh

There are no comments yet.

Please log in to write the first comment.